Adverse Effects of Psychotropic Drugs in Old Age

Total Page:16

File Type:pdf, Size:1020Kb

Adverse Effects of Psychotropic Drugs in Old Age Adverse Effects of Psychotropic Drugs in Old Age Jon Albin Brännström Adverse Effects of Psychotropic Drugs in Old Age Jon Albin Brännström Department of Community Medicine and Rehabilitation, Geriatric Medicine Umeå & Skellefteå 2020 Responsible publisher under Swedish law: the Dean of the Medical Faculty This work is protected by the Swedish Copyright Legislation (Act 1960:729) Dissertation for PhD ISBN: 978-91-7855-357-0 (print) ISBN: 978-91-7855-358-7 (pdf) ISSN: 0346-6612 New Series No: 2098 Electronic version available at: http://umu.diva-portal.org/ Printed by: Cityprint i Norr AB Umeå, Sweden 2020 Drugs are bad, m’kay -Mr. Mackey Table of Contents Table of Contents ..................................................................... i Abstract ................................................................................. iii Abbreviations ......................................................................... v Original papers ..................................................................... vii Populärvetenskaplig sammanfattning ................................. viii Introduction and Background ................................................ 1 Psychiatric disorders and symptoms in old age ..................................... 2 Major neurocognitive disorder .......................................................... 2 Neuropsychiatric symptoms of major neurocognitive disorder ...... 3 Depression ........................................................................................... 4 Anxiety and Sleep-wake disorders ..................................................... 4 Schizophrenia ...................................................................................... 5 Psychotropic Drugs ................................................................................. 6 Antipsychotics ..................................................................................... 8 Antidepressants ................................................................................. 14 Anxiolytics and hypnotics ................................................................. 21 Adverse Effects of Psychotropic Drugs ................................................. 24 Antipsychotics ................................................................................... 27 Antidepressants ................................................................................. 35 Anxiolytics and hypnotics ................................................................. 40 Aims ..................................................................................... 43 Materials and Methods ......................................................... 44 Data sources .......................................................................................... 45 Umeå 85+/GERDA ............................................................................ 45 FOPANU ............................................................................................ 46 REMANU ........................................................................................... 46 UMDEX .............................................................................................. 46 Registers ............................................................................................ 47 Participants ........................................................................................... 48 Paper I ............................................................................................... 48 Paper II .............................................................................................. 48 Paper III ............................................................................................ 51 Paper IV ............................................................................................. 51 i Materials and Methods (continued) Measurements, exposures and outcomes (Papers I and II) ................ 52 Measurements, exposures and outcomes (Papers III and IV) ............ 55 Statistics ................................................................................................ 57 General .............................................................................................. 57 Mortality ............................................................................................ 57 Hip fracture ....................................................................................... 57 Statistics specific for each paper ...................................................... 58 Ethics ................................................................................... 63 Results .................................................................................. 64 Antidepressants and mortality in the very old (Paper I) ..................... 64 Psychotropic drugs and mortality in major NCD (Paper II) ............... 68 Antidepressants and hip fracture (Paper III) ..................................... 73 Antipsychotics and hip fracture (Paper IV) ......................................... 79 Discussion ............................................................................ 87 Main findings ........................................................................................ 87 Psychotropic drug use and mortality (Papers I and II) ...................... 88 Methodology - strengths and limitations ........................................ 88 Antidepressants and mortality ......................................................... 89 Antipsychotics and mortality ........................................................... 91 Anxiolytics and hypnotics and mortality ......................................... 92 Psychotropic drug use and hip fracture (Papers III and IV) ............... 93 Methodology - strengths and limitations ......................................... 93 Antidepressants and hip fracture ..................................................... 95 Antipsychotics and hip fracture ....................................................... 97 Prevalence of psychotropic drug use .................................................. 100 Implications ........................................................................................ 103 Conclusions ......................................................................... 107 Acknowledgements ............................................................. 108 References .......................................................................... 109 Papers I-IV List of dissertations ii Abstract Background With increasing age, the body and mind transform. Many of our organs gradually lose capacity, making them more sensitive to the effects of several drugs. In parallel, many of us accumulate an increasing burden of disease and other conditions warranting the use of medications. Hence, the use of most classes of drugs increases with age, especially so in elderly women. At the same time, medical science is lagging behind due to the fact that the oldest people in society often are excluded from pharmacological studies, where young males are the most coveted subjects. In the absence of strong evidence, much of the knowledge about the clinical and adverse effects of several drugs in the elderly is derived from observational studies, prone to bias and confounding. The use of psychotropic drugs in elderly people is particularly controversial, and even more so in people suffering from major neurocognitive disorders (NCD). Psychotropics have been associated with several adverse effects as well as limited clinical effect. Still, they are frequently prescribed to elderly patients. Aims This thesis aims to explore the associations between several types of psychotropic drugs and two of the most severe adversities attributed to their use, increased mortality and the risk of hip fracture. It aims to explore mortality in data from well-controlled studies. It also aims to employ novel statistical methods to investigate the associations between drug exposure and hip fracture, in an attempt to gain information on possible causality from observational data. Methods This thesis uses quantitative, comparative and epidemiological methods, prospective as well as retrospective. Two of the four papers are based on data collections conducted by the Department of Community Medicine and Rehabilitation, Umeå University, and include 992 and 1,037 individuals, respectively. The other two papers are based on Swedish nationwide registers and include 408,144 and 255,274 subjects, respectively. In all four papers multivariable regression models were used to investigate the associations between the exposures and outcomes, adjusted for possible confounding variables. Results In a population-based sample of very old people, and in old people with major NCD, ongoing use of psychotropic drugs was not independently associated with increased mortality. Analyses did show, however, a significant impact of sex on iii the mortality risk, with tendencies for antidepressant drug use to be protective in men, but not in women, and for benzodiazepines to increase the mortality risk in men, but not in women. In two cohorts of old people, based on several nationwide registers, investigating the associations between psychotropic drug use and hip fracture revealed that users of antidepressants, as well as users of antipsychotics, had significantly increased risks of hip fracture, independent of a wide range of covariates. However, when studying how the risk changed over time, the strongest associations were found before the initiation of treatment
Recommended publications
  • Antidepressant Discontinuation Syndrome CHRISTOPHER H
    Antidepressant Discontinuation Syndrome CHRISTOPHER H. WARNER, MAJ, MC, USA, Winn Army Community Hospital, Fort Stewart, Georgia WILLIAM BOBO, LCDR, MC, USN, Uniformed Services University of the Health Sciences, Bethesda, Maryland CAROLYNN WARNER, MAJ, MC, USA, Winn Army Community Hospital, Fort Stewart, Georgia SARA REID, CPT, USAF, MC, Bolling Air Force Base, Washington, D.C. JAMES RACHAL, MAJ, USAF, MC, Ehrling Berquist Air Force Hospital, Offutt Air Force Base, Omaha, Nebraska Antidepressant discontinuation syndrome occurs in approximately 20 percent of patients after abrupt discontinuation of an antidepressant medication that was taken for at least six weeks. Typical symptoms of antidepressant discontinuation syndrome include flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal. These symptoms usu- ally are mild, last one to two weeks, and are rapidly extinguished with reinstitution of antide- pressant medication. Antidepressant discontinuation syndrome is more likely with a longer duration of treatment and a shorter half-life of the treatment drug. A high index of suspicion should be maintained for the emergence of discontinuation symptoms, which should prompt close questioning regarding accidental or purposeful self-discontinuation of medication. Before antidepressants are prescribed, patient education should include warnings about the potential problems associated with abrupt discontinuation. Education about this common and likely underrecognized clinical phenomenon will help prevent future episodes
    [Show full text]
  • A Novel Atypical Antidepressant That May Provide New Insights Into the Biomolecular Basis of Depression
    Recent Patents on CNS Drug Discovery, 2006, 1, 29-41 29 Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression Christiaan B. Brink*, Brian H. Harvey and Linda Brand Division of Pharmacology, North-West University (PUK), Potchefstroom, 2520, South Africa Received: July 29, 2005; Accepted: September 05, 2005; Revised: September 12, 2005 Abstract: Tianeptine, an atypical antidepressant patented and developed by Servier, enhances the synaptic reuptake of serotonin, without affecting norepinephrine and dopamine uptake, while it lacks affinity for neurotransmitter receptors. This mechanism for an antidepressant is apparently paradoxical, since the currently employed antidepressants enhance serotonin by inhibiting its breakdown or by inhibiting monoaminergic reuptake. Although tianeptine has been shown to reduce central 5HT availability and to indirecty modulate central adrenergic and dopaminergic systems and to indirectly inhibit cholinergic hyperactivity, its antidepressant action is believed to be more directly related to central neuronal remodeling and restoration of neuronal plasticity. In reliable animal models of depression tianeptine has been shown to prevent neurodegeneration and decreases in hippocampal volume in response to chronic stress. These effects on neuroplasticity are suspected to involve the normalization of the hypothalamic-pituitary-adrenal axis and modulatory effects on excitatory amino acids and N-methyl-D-aspartate receptors. Together with a body of related studies, these data provide further support for the hypothesis that depression may involve dysregulation of pathways controlling cellular resilience and that treatment should be directed towards the reversal thereof. Importantly, tianeptine is not anxiogenic and has also been shown to be effective in treatment-resistant depression, which may lead the way to a major breakthrough in the treatment of depression.
    [Show full text]
  • The Repurposing Drugs in Oncology Database
    ReDO_DB: the repurposing drugs in oncology database Pan Pantziarka1,2, Ciska Verbaanderd1,3, Vidula Sukhatme4, Rica Capistrano I1, Sergio Crispino1, Bishal Gyawali1,5, Ilse Rooman1,6, An MT Van Nuffel1, Lydie Meheus1, Vikas P Sukhatme4,7 and Gauthier Bouche1 1The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium 2The George Pantziarka TP53 Trust, London, UK 3Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium 4GlobalCures Inc., Newton, MA 02459 USA 5Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA 6Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium 7Emory University School of Medicine, Atlanta, GA 30322 USA Correspondence to: Pan Pantziarka. Email: [email protected] Abstract Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity looking at the use of non-cancer drugs as possible cancer treatments. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. Data from 268 drugs have been included in a database (ReDO_DB) developed by the ReDO project. Summary results are outlined and an assessment Research of clinical trial activity also described. The database has been made available as an online open-access resource (http://www.redo-project. org/db/). Keywords: drug repurposing, repositioning, ReDO project, cancer drugs, online database Published: 06/12/2018 Received: 27/09/2018 ecancer 2018, 12:886 https://doi.org/10.3332/ecancer.2018.886 Copyright: © the authors; licensee ecancermedicalscience.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson Et Al
    US006319953B1 (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson et al. (45) Date of Patent: *Nov. 20, 2001 (54) TREATMENT OF DEPRESSION AND WO 95/08549 3/1995 (W0). ANXIETY WITH FLUOXETINE AND AN WO 95/18124 7/1995 (W0). NK-1 RECEPTOR ANTAGONIST W0 96/05181 2/1996 (W0). W0 96/18643 6/1996 (W0). (75) Inventors: Emma Joanne Carlson, Puckeridge; W0 96/19233 6/1996 (W0). Nadia Melanie Rupniak, Bishops W0 96/24353 8/1996 (W0). W0 98/15277 4/1998 (W0). Stortford, both of (GB) OTHER PUBLICATIONS (73) Assignee: Merck Sharp & Dohme Ltd., Hoddesdon (GB) Aguiar, M., et al., Physiology& Behavior, 1996, 60(4) 1183—1186. ( * ) Notice: Subject to any disclaimer, the term of this Barden, N., et al., J. Neurochem., 1983, 41, 834—840. patent is extended or adjusted under 35 BristoW, L., et al., Eur J. Pharmacol., 1994, 253, 245—252. U.S.C. 154(b) by 0 days. Brodin, E., et al., Neuropharmacology, 1987, 26(6) 581—590. This patent is subject to a terminal dis Brodin, E., et al., Neuropeptides, 1994, 26, 253—260. claimer. Culman, J., et al., J. Physiol. Pharmacol., 1995, 73, 885—891. Cutler, et al., J. Psychopharmacol, 1994, 8, A22, 87. (21) Appl. N0.: 09/457,241 Elliott, P. J., Exp. Brain Res. UK, 1988, 73, 354—356. (22) Filed: Dec. 8, 1999 F—D—C Reports—Prescription Pharmaceuticals and Bio technology, Dec. 8, 1997, 59(49), 10. Related US. Application Data File, S. E., Pharm. Biochem. Behavior, 1997, 58, 3, 747—752. (60) Division of application No.
    [Show full text]
  • Management of Major Depressive Disorder Clinical Practice Guidelines May 2014
    Federal Bureau of Prisons Management of Major Depressive Disorder Clinical Practice Guidelines May 2014 Table of Contents 1. Purpose ............................................................................................................................................. 1 2. Introduction ...................................................................................................................................... 1 Natural History ................................................................................................................................. 2 Special Considerations ...................................................................................................................... 2 3. Screening ........................................................................................................................................... 3 Screening Questions .......................................................................................................................... 3 Further Screening Methods................................................................................................................ 4 4. Diagnosis ........................................................................................................................................... 4 Depression: Three Levels of Severity ............................................................................................... 4 Clinical Interview and Documentation of Risk Assessment...............................................................
    [Show full text]
  • Journal of Psychiatry
    Soares et al., J Psychiatry 2014, 17:6 Journal of Psychiatry http://dx.doi.org/10.4172/1994-8220.1000160 Research Article Open Access Depression and Cognitive Decline: Factors Related to Demographics and Psycho Pharmacotherapy on Elderly in Nursing Homes Edvaldo Soares1* and Patrícia de Souza Rossignoli2 1,2Sao Paulo State University, Laboratory of Cognitive Neuroscience-LaNeC *Corresponding author: Edvaldo Soares, Sao Paulo State University, Av. Hygino Muzzi Filho, 737,Marília, São Paulo, Brazil. CEP: 17500-090; Tel: 551434021371; E-mail: [email protected] Received Date: May 5, 2014, Accepted Date: September 23, 2014, Published Date: September 30, 2014 Copyright: © 2014, Edvaldo Soares et al., This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Objectives: To identify the prevalence of neuropsychiatric disorders, especially DP and CD, on a sample of nursing home residents, relating this prevalence with some aspects of the demographics and psycho pharmacotherapy. Methods: 48 elders from two different nursing homes were selected. The collection of demographic and pharmacological data was made utilizing medical records. The medication was classified according to the Anatomical Therapeutic Chemical Code (ATC) criteria. The Geriatric Depression Scale (GDS 30) and the Mini Mental State Examination (MMSE) tests were utilized to determine the prevalence of DP and CD. Results: It was observed in the sample a high incidence of DP and CD among the researched elders. More schooling individuals tend to present less CD. Individuals with less CD indicatives present less symptomatology for DP.
    [Show full text]
  • Summary of Product Characteristics 1. Name Of
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Iloprost Pharmamentum 50 micrograms/0.5 ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 0.5 ml of aqueous solution contains 67 micrograms of Iloprost trometamol (equivalent to 50 micrograms of iloprost). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, colourless solution with no visible particles. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of advanced thromboangiitis obliterans (Buerger’s disease), with severe circulation disturbances, in cases where revasculariation is not indicated. 4.2 Posology and method of administration The treatment with Iloprost Pharmamentum should be performed under strict monitoring in hospitals or clinics that have suitable equipment. Before initiating the treatment in women, pregnancy must be ruled out. Iloprost Pharmamentum is administered after dilution, as described in section 6.6 “Special precautions for disposal”, as an intravenous infusion, for a period of 6 hours/day, through a peripheral vein or a central catheter into a vein. The dose will be adjusted according to the individual tolerability within a dosage range of 0.5 to 2.0 ng iloprost/kg of body weight/min. The solution for infusion should be prepared daily to ensure its sterility. The content of the ampoule and solvent must be completely mixed. Blood pressure and heart rate should be monitored at the beginning of the infusion and after each dose increase. During the first 2 to 3 days the dose tolerated by the patient will be determined. In order to do this, the treatment should start with an infusion rate that supplies a dose of 0.5 ng/kg/min, for 30 minutes.
    [Show full text]
  • Ewg 2015 Expert Working Group Actilyse
    EWG 2015 EXPERT WORKING GROUP ACTILYSE (A LTEPLASE) B ALANCE OF BENEFI TS AND RISKS WHEN USED IN THE TREATMENT OF ACUTE ISCHAEMIC STROKE Title of paper: Paper 8: Risk minimisation measures Product: Assessors: Actilyse 10, 20, 50mg Medical assessor: Dr Scientific assessors: Dr Dr MAHs: Previous Assessments: Boehringer Ingelheim Limited CHM May 2014 EWG: Nov 2014, Jan 2015 Active constituents: Legal status: Alteplase (rt-PA) POM Therapeutic classification: Antithrombotic agent, ATC code B01AD02 Contents Page 1. Introducti on 3 2. Current risk minimisation measures in place in the UK 3 3. Current national guidelines in the UK 4 4. Dis cussion and conclusions 7 Annex 1: Proposals for SmPC updates 9 Annex 2: Actilyse SmPC and PIL 11 2 1. Introduction This paper discusses the current risk minimisation measures in place for rt-PA and their appropriateness and adequacy. Paper 9 discusses other communications documents and risk assessment tools that are currently in use, or planned, and the whether there is a need for further materials to aid clinical decision making and patient understanding of the benefits and risks of rt-PA treatment. A distinction has been drawn between formal risk minimisation measures (measures that form part of the product’s licence and which would therefore need to be agreed and applied in all member states where the mutual recognition authorisation is valid) and communications documents and other measures (information provided on a national basis, e.g. by the regulatory authority itself, or under a less formal agreement with the MAH, or by a professional body/patient organisation). 2.
    [Show full text]
  • Approved Abstracts PCNE Working Conference 2015, Mechelen, Belgium
    Approved abstracts PCNE Working Conference 2015, Mechelen, Belgium Poster presentations 23. Experiences of using prescription medicines among the general public in the UK- a comparison of paper- and online-reported experiences Katusiime -Barbra, O’ Grady -Máiréad, Vaghji- Chandra, Rubaseyone - Rubanah, Corlett- Sarah, Krska - Janet. ([email protected]) Medway School of Pharmacy, The Universities of Kent and Greenwich, Central Avenue, Chatham Maritime, Kent,UK ME4 4TB . Background Regular use of prescription medicines can impact on an individual’s quality of life and create treatment burden. Health professionals require appropriate methods to identify patients’ experiences of medicines use. Patient-reports provide a more direct assessment of such experiences. Different methods of questionnaire-administration may reveal varied medicine-related experiences. Purpose This study aimed to compare paper- and online-reported experiences of using regular prescription medicines among adults living in the UK. Method Paper- and online-versions of the Living with Medicines Questionnaire© were used. This 60 item, 5-Likert-type (strongly agree to strongly disagree), questionnaire covers 8 domains: Relationships with health professionals, Practicalities, Information, Efficacy, Side- effects, Attitudes, Impact and Control. Paper questionnaires were distributed to community pharmacy users, and the general public of South-East England. The online survey was promoted via links on patient health websites, social media, and flyers. Inclusion criteria were: adults, living in the UK, and using regular prescription medicines. Using SPSS version 22, Chi-square tests were conducted to examine significant differences (p<0.05) in reported experiences between these methods. Institutional ethical approval was granted. Findings 1174 individuals completed the survey via paper (43.1%, n=506), and online (56.9%, n=668).
    [Show full text]
  • Vortioxetine: a Comprehensive Update on a New- Generation Antidepressant
    DOI: 10.14744/DAJPNS.2021.00115 Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2021;34:1-13 EDITORIAL Vortioxetine: a comprehensive update on a new- generation antidepressant Cuneyt Evren1 1Bakirkoy Training and Research Hospital for Psychiatry Neurology and Neurosurgery, Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM), Istanbul - Turkey Major depressive disorder (MDD) is a chronic of depressive patients had a sufficient response to a disease defined by one or more major depressive single antidepressant (8) and that remission was lower episodes lasting at least two weeks and no history of in patients with two failed treatments (9). Approximately manic episodes (1). MDD affects approximately 6% of half of patients respond poorly to first-line the world’s adult population each year and is about antidepressant treatment (10). Moreover, current twice as common in women than men (2). This disorder treatments often have side effects (11). A recent increases suicide and some important medical illnesses systematic review and meta-analysis investigated the such as diabetes (3). According to the World Health efficacy and safety of pharmacological and non- Organization (WHO), depressive disorders are the pharmacological treatments for MDD (12). According single largest contributor to non-fatal health loss (7.5% to the results, with the exception of probiotics, all of the of Years Lived with Disability) (4). treatments studied (acupuncture, mirtazapine, herbal Although psychotherapy and electroconvulsive medicine, venlafaxine, physical exercise, cognitive- therapy are used, pharmacotherapy is still typically a behavioral therapy, bupropion, fluoxetine, and primary form of treatment for MDD (5). Tricyclic vortioxetine) appeared to be significantly more effective antidepressants (TSA) and monoamine oxidase than placebo.
    [Show full text]
  • Impact of the World Health Organization Pain Treatment
    medicina Article Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study Skaiste˙ Kasciuškeviˇciut¯ e˙ 1,* ID , Gintautas Gumbreviˇcius 1, Aušra Vendzelyte˙ 2, Arunas¯ Šˇciupokas 3 ID , K˛estutisPetrikonis 3 and Edmundas Kaduševiˇcius 1 1 Division of Clinical Pharmacology, Institute of Physiology and Pharmacology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania; [email protected] (G.G.); [email protected] (E.K.) 2 Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania; [email protected] 3 Department of Neurology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania; [email protected] (A.S.); [email protected] (K.P.) * Correspondence: [email protected]; Tel.: +37-060-304-903 Received: 27 February 2018; Accepted: 8 May 2018; Published: 11 May 2018 Abstract: Background and objective: Irrational use of nonsteroidal anti-inflammatory drugs (NSAIDs) is the main cause of adverse effects-associated hospitalizations among all medication groups leading to extremely increased costs for health care. Pharmacoepidemiological studies can partly reveal such issues and encourage further decisions. Therefore, the aim of our study was to evaluate the utilization of non-opioid analgesics (ATC classification N02B and M01A) in Lithuania, and to compare it with that of other Baltic and Scandinavian countries in terms of compliance to the WHO pain treatment guidelines and the EMA safety recommendations on NSAID use. Materials and methods: The dispensing data were obtained from the sales analysis software provider in the Baltic countries (SoftDent, Ltd., Kaunas, Lithuania); State Medicine Control Agencies of Lithuania, Latvia, and Estonia; Norwegian Prescription Database; Swedish Database for Medicines; and Danish Prescription Database.
    [Show full text]
  • Role of Mu-Opioid Receptors in the Behavioral Effects of the Antidepressant
    Role of Mu-Opioid Receptors in the Behavioral Effects of the Antidepressant Tianeptine Jaena Han Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2021 © 2021 Jaena Han All Rights Reserved Abstract Role of Mu-Opioid Receptors in the Behavioral Effects of the Antidepressant Tianeptine Jaena Han For over half a century, the monoamine hypothesis has been the dominant theoretical framework guiding depression research and drug development. This hypothesis posits that depression arises from a deficiency in the monoaminergic neurotransmitters serotonin, norepinephrine, and possibly dopamine, and that antidepressants function by increasing extracellular availability of these monoamines in the brain, especially at the synaptic level. It is clear however, that the monoamine hypothesis cannot fully explain either the pathophysiology of depression nor the mechanisms of antidepressant action. Tianeptine is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs). The recent discovery that tianeptine is a mu opioid receptor (MOR) and delta opioid receptor (DOR) agonist has provided a potential avenue for expanding our understanding of antidepressant treatment beyond the monoamine hypothesis. This dissertation aims to understand the neural circuits underlying tianeptine’s antidepressant effects. We first characterized the acute and chronic effects of tianeptine on depressive-like and other opioid-related behaviors in mice, and used genetic and pharmacological models to test whether these behavioral effects are mediated by MOR and/or DOR. We found that acute tianeptine administration produced an antidepressant-like reduction in immobility time in the forced swim test, as well as classic opioid-like effects including analgesia, hypophagia, hyperactivity, and conditioned place preference.
    [Show full text]